Heron Therapeutics Inc. (NASDAQ:HRTX) shares traded up 6.9% on Tuesday . The stock traded as high as $18.92 and last traded at $18.06, with a volume of 1,265,450 shares trading hands. The stock had previously closed at $16.90.

Several research analysts recently weighed in on the company. Jefferies Group reissued a “buy” rating on shares of Heron Therapeutics in a research report on Monday, April 18th. Cowen and Company reissued a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Cantor Fitzgerald reissued a “buy” rating and set a $41.00 price target on shares of Heron Therapeutics in a research report on Friday, June 24th. Leerink Swann reissued a “buy” rating on shares of Heron Therapeutics in a research report on Monday, June 27th. Finally, Noble Financial reissued a “buy” rating and set a $51.00 price target on shares of Heron Therapeutics in a research report on Wednesday, April 20th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $50.30.

The firm has a 50-day moving average of $17.48 and a 200 day moving average of $18.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.92). Equities analysts anticipate that Heron Therapeutics Inc. will post ($3.59) earnings per share for the current fiscal year.

Other hedge funds and institutional investors recently bought and sold shares of the company. Bank of Montreal Can bought a new position in Heron Therapeutics during the fourth quarter valued at about $3,010,000. GAM Holding AG raised its position in Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock valued at $1,119,000 after buying an additional 9,400 shares in the last quarter. California Public Employees Retirement System raised its position in Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares in the last quarter. Swiss National Bank bought a new position in Heron Therapeutics during the fourth quarter valued at about $1,100,000. Finally, California State Teachers Retirement System raised its position in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares in the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.